Gritstone bio, Inc. Common Stock
GRTS
GRTS was delisted on the 21st of October, 2024.
88 hedge funds and large institutions have $99.5M invested in Gritstone bio, Inc. Common Stock in 2023 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 26 closing their positions.
1,154% more call options, than puts
Call options by funds: $991K | Put options by funds: $79K
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less first-time investments, than exits
New positions opened: 25 | Existing positions closed: 26
2% less funds holding
Funds holding: 90 → 88 (-2)
23% less capital invested
Capital invested by funds: $129M → $99.5M (-$29.1M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$10M |
| 2 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$6.48M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.9M |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.18M |
| 5 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
+$1.59M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
-$6.46M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$2.39M |
| 3 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.5M |
| 4 |
Marshall Wace
London,
United Kingdom
|
-$1.17M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
-$1.15M |
GRTS Hedge Fund Activity: Q2 2023 in Review
88 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Gritstone bio, Inc. Common Stock (GRTS) for Q2 2023, worth a combined $99.5M — down 23% from $129M a quarter earlier.
Sellers outnumbered buyers: 26 funds closed out of GRTS and 25 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 26 added.
The largest buyer was BlackRock, adding an estimated $10M. The largest seller was Frazier Life Sciences Management, cutting an estimated $6.46M.
- 88 institutional investors held Gritstone bio, Inc. Common Stock (GRTS) as of Q2 2023, down from 90 in Q1 2023.
- Funds reported $99.5M of Gritstone bio, Inc. Common Stock stock for Q2 2023, down 23% quarter-over-quarter.
- 25 funds opened new Gritstone bio, Inc. Common Stock positions in Q2 2023 and 26 closed out, a net change of -1 holder.
- The largest Gritstone bio, Inc. Common Stock buyer in Q2 2023 was BlackRock, an estimated $10M added.
- The largest Gritstone bio, Inc. Common Stock seller in Q2 2023 was Frazier Life Sciences Management, an estimated $6.46M sold.
Based on aggregated 13F filings for Q2 2023.